Moderna Stock Rockets Over 100% on Cancer Vaccine Success

Moderna shares saw a massive jump of over 100% in Wednesday pre market trading, reaching $122.51. This surge followed news that the company and Merck achieved positive Phase 3 results for a personalized cancer vaccine. The treatment uses mRNA technology to target individual tumor mutations, helping the immune system fight aggressive skin cancer more effectively than current standard treatments.

This trial represents a major milestone in medical history. The study showed that patients receiving the experimental shot alongside Merck’s Keytruda remained cancer free for longer than those treated with Keytruda alone. This is the first time an mRNA based cancer therapy has reached this level of success in a Phase 3 trial.

The stock had previously struggled after the COVID 19 pandemic, dropping significantly from its 2021 highs. However, this breakthrough combined with other progress in the company pipeline has sparked a major rally. While investors remain cautious as full data is still pending, the news has pushed the stock up significantly while Merck shares also saw gains of about 6%.

Looking ahead, the market is waiting to see how these gains hold up when the regular trading session begins. The companies intend to present full trial details at upcoming medical meetings and initiate discussions with health regulators. With the same treatment being tested for other types of cancer, this news highlights a potentially important shift in how we approach cancer therapy.